Literature DB >> 16784410

Treatment of dystonia.

Roongroj Bhidayasiri1, Daniel Tarsy.   

Abstract

Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary movements, improve posture and function and reduce associated pain. Therapeutic options are dictated by clinical assessment of the topography of dystonia, severity of abnormal movements, functional impairment and progression of disease and consists of pharmacological, surgical and supportive approaches. Several advances have been made in treatment with newer medications, availability of different forms of botulinum toxin and globus pallidus deep brain stimulation (DBS). For patients with childhood-onset dystonia, the majority of whom later develop generalized dystonia, oral medication is the mainstay of therapy. Recently, DBS has emerged as an effective alternative therapy. Botulinum toxin is usually the treatment of choice for those with adult-onset primary dystonia in which dystonia usually remains focal. In patients with secondary dystonia, treatment is challenging and efficacy is typically incomplete and partially limited by side effects. Despite these treatment options, many patients with dystonia experience only partial benefit and continue to suffer significant disability. Therefore, more research is needed to better understand the underlying cause and pathophysiology of dystonia and to explore newer medications and surgical techniques for its treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784410     DOI: 10.1586/14737175.6.6.863

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

1.  In vivo neurochemistry of primary focal hand dystonia: a magnetic resonance spectroscopic neurometabolite profiling study at 3T.

Authors:  Priyantha Herath; Cecile Gallea; Jan Willem van der Veen; Silvina G Horovitz; Mark Hallett
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

Review 2.  New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy.

Authors:  Diane L Damiano; Katharine E Alter; Henry Chambers
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

3.  Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

Review 4.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 5.  Deep brain stimulation.

Authors:  X L Chen; Y Y Xiong; G L Xu; X F Liu
Journal:  Interv Neurol       Date:  2013-09

Review 6.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

Review 7.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

Review 8.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

9.  Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study.

Authors:  Vijay P Misra; Edvard Ehler; Benjamin Zakine; Pascal Maisonobe; Marion Simonetta-Moreau
Journal:  BMJ Open       Date:  2012-06-14       Impact factor: 2.692

Review 10.  Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.

Authors:  J Ng; S J R Heales; M A Kurian
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.